|
Selected genes derived from ICA & GO analysis of gene array experiments. Genes are combined into ontologies. Average Fold Changes are calculated from normalised values over the number of spots shown for each gene. As can be seen, not all genes are differentially expressed according to t-test p-values. Genes are instead selected based on their ICA loading (see discussion) |
|||||
| GO Description |
Gene symbol |
Description |
No of spots |
Ave FC |
Ave ttest p |
|
|
|||||
| activation of MAPKKK (GO:0000185) |
GADD45B |
growth arrest and DNA-damage-inducible, beta |
2 |
2.6 |
0.090 |
| cell cycle arrest (GO:0007050) |
EIF4G2 |
eukaryotic translation initiation factor 4 gamma, 2 |
2 |
1.2 |
0.249 |
| GADD45A |
growth arrest and DNA-damage-inducible, alpha |
2 |
5.1 |
0.003 |
|
| PPP1R15A |
protein phosphatase 1, regulatory (inhibitor) subunit 15A |
2 |
1.4 |
0.085 |
|
| PR48 |
protein phosphatase 2A 48 kDa regulatory subunit |
1 |
-1.1 |
0.427 |
|
| SESN3 |
sestrin 3 |
2 |
-1.3 |
0.161 |
|
| TP53 |
tumor protein p53 (Li-Fraumeni syndrome) |
4 |
1.7 |
0.036 |
|
| cell death (GO:0008219) |
EIF4G2 |
eukaryotic translation initiation factor 4 gamma, 2 |
2 |
1.2 |
0.249 |
| EMP3 |
epithelial membrane protein 3 |
2 |
1.7 |
0.111 |
|
| cell growth (GO:0016049) |
P8 |
p8 protein (candidate of metastasis 1) |
2 |
3.1 |
0.005 |
| SLC3A2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
4 |
2.0 |
0.012 |
|
| cell proliferation (GO:0008283) |
EGFR |
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) |
2 |
2.2 |
0.009 |
| FTH1 |
ferritin, heavy polypeptide 1 |
1 |
1.2 |
0.301 |
|
| IGFBP4 |
insulin-like growth factor binding protein 4 |
2 |
1.8 |
0.002 |
|
| OSMR |
oncostatin M receptor |
2 |
1.7 |
0.088 |
|
| PDGFA |
platelet-derived growth factor alpha polypeptide |
2 |
1.5 |
0.032 |
|
| PDGFB |
platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) |
4 |
2.2 |
0.083 |
|
| SYK |
spleen tyrosine kinase |
2 |
-1.1 |
0.631 |
|
| TGFA |
transforming growth factor, alpha |
2 |
-1.0 |
0.907 |
|
| TGFBI |
transforming growth factor, beta-induced, 68kDa |
2 |
2.1 |
0.164 |
|
| TP53 |
tumor protein p53 (Li-Fraumeni syndrome) |
4 |
1.7 |
0.036 |
|
| VEGF |
vascular endothelial growth factor |
2 |
6.6 |
0.175 |
|
| G1/S transition of mitotic cell cycle (GO:0000082) |
CCND1 |
cyclin D1 (PRAD1: parathyroid adenomatosis 1) |
2 |
-1.3 |
0.168 |
| insulin-like growth factor binding (GO:0005520) |
CYR61 |
cysteine-rich, angiogenic inducer, 61 |
2 |
2.9 |
0.013 |
| KAZALD1 |
Kazal-type serine protease inhibitor domain 1 |
2 |
-1.1 |
0.770 |
|
| IGFBP4 |
insulin-like growth factor binding protein 4 |
2 |
1.8 |
0.002 |
|
| CTGF |
connective tissue growth factor |
2 |
2.9 |
0.006 |
|
| IGFBP5 |
insulin-like growth factor binding protein 5 |
4 |
2.7 |
0.041 |
|
| metalloprotease inhibitor (GO:0008191) |
TIMP1 |
tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) |
3 |
1.4 |
0.250 |
| methionine adenosyltransferase (GO:0004478) |
MAT2A |
methionine adenosyltransferase II, alpha |
4 |
-2.9 |
0.001 |
| methionine-tRNA ligase (GO:0004825) |
MARS |
methionine-tRNA synthetase |
2 |
6.7 |
0.006 |
Saidi et al. Molecular Cancer 2006 5:13 doi:10.1186/1476-4598-5-13 |
|||||